Mapping the Impact of Gut Microbiota on Brain and Behavior Through the Lens of GABA

ConditionHealthy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-50
SponsorUniversity of Reading

About this trial

Gut microbiota produce different metabolites within the human body, which include neurotransmitters. Animal studies have demonstrated a critical role for the gut microbiota in various aspects of brain and behavioural function, and a smaller number of studies in humans have shown differences of gut microbiota composition in psychiatric conditions. However, almost nothing is known about the impact of neurotransmitters produced by the gut microbiota on human brain and behaviour.

The way in which differences in brain, behaviour and personality traits are associated with the gut microbiota, and how they are influenced by a probiotic will be explored, with a special focus on GABA (Gamma Amino Butyric Acid).

Abnormalities of microbiota composition have been identified in metabolic disorders, such as inflammatory bowel disease and obesity, and psychiatric conditions, such as depression and anxiety.

The aim of this intervention trial will be to answer the following fundamental questions:

1. Does the population of gut bacteria capable of producing GABA modulate brain-based measures of GABA? 2. Does the population of gut bacteria capable of producing GABA influence performance in behavioural tasks known to depend on GABA-ergic function?

The impact of a GABA producing probiotic on the measures of GABA in the brain and serum, relevant metabolites in blood, faecal and urine samples and performance in GABA dependent behavioural tasks will be investigated in this trial.

Eligibility criteria

Qualifiers

Male

Right-handed

Caucasian/White

Between 18 and 50 years of age

Disqualifiers

Use of antibiotics within the last 3 months

Use of protonic pump inhibitors (PPIs) within the last 3 months

Current or history of regular smoking within the last 6 months

Regular consumption of >14 units of alcohol per week

Trial design

Treatments tested in this trial

  • Probiotic
  • Placebo

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Reading

Lead sponsor

European Research Council

Collaborator